tbuckley/cabot-search huggingface dataset:
Correction
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Update: Outbreak of Hantavirus Infection—Southwestern United States, 1993
Journal: JAMA (1993)

An outbreak of illness associated with hantavirus infection continues to be investigated by state health departments in New Mexico, Arizona, Colorado, and Utah; the Indian Health Service; and CDC, with the assistance of the Navajo Nation Division of Health. This report updates information regarding the outbreak and presents information on two cases that occurred in the 10 months preceding this outbreak.
Mutagenic and Carcinogenic Significance and the Possible Induction of Lung Cancer by Nitro Aromatic Hydrocarbons in Particulate Pollutants
Authors: Hiroshi Tokiwa, Nobuyuki Sera, Akio Nakashima, Koichi Nakashima, Yoichi Nakanishi, Nobuaki Shigematu
Journal: Environmental Health Perspectives (1994)
Tetanus
Authors: Robert J. Rothstein
Journal: JAMA (1978)

DESPITE the willingness of physicians to provide tetanus toxoid boosters to patients with a wide variety of wounds, the disease produced by the neurotoxin liberated by<i>Clostridium tetani</i>continues to be a serious health problem. An estimated 50,000 people die annually from tetanus throughout the world.<sup>1</sup>In 1975, there were 102 cases, with 45 fatalities in the United States.<sup>2</sup> Physicians who frequently encounter patients with fresh wounds or who may be faced with a case of developing tetanus should be aware of both prophylactic immunization schedules and the treatment of patients with established tetanus. <h3>Prevention</h3> The major contribution the physician can make to reduction of morbidity and mortality from tetanus is prevention of the disease. Fortunately, it is completely preventable through adequate immunization and proper wound care. Tetanus occurs only in patients who have not had adequate primary immunization or who have not received adequate immunization boosters since
Maternal Vitamin A Supplementation and Lung Function in Offspring
Journal: New England Journal of Medicine (2010)

In the "Characteristics of the Study Population" subsection of Results (page 1787), the first sentence of the final paragraph should have begun, "In 1322 (96%) of the 1371 children who underwent spirometry . . .," rather than "In 1322 (96%) of the 1377 children . . .."We regret the error.
RECOGNITION OF A COMMON BACTERIAL INFECTION OF THE SKIN
Journal: JAMA (1961)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE STUMP IN APPENDICECTOMY
Authors: A. W. M. Robson
Journal: BMJ (1905)

<h3>ABSTRACT</h3> Wilms tumor (WT) is the most common renal malignancy of childhood. Despite improvements in the overall survival, relapse occurs in ~15% of patients with favorable histology WT (FHWT). Half of these patients will succumb to their disease. Identifying novel targeted therapies in a systematic manner remains challenging in part due to the lack of faithful preclinical <i>in vitro</i> models. We established ten short-term patient-derived WT cell lines and characterized these models using low-coverage whole genome sequencing, whole exome sequencing and RNA-sequencing, which demonstrated that these ex-vivo models faithfully recapitulate WT biology. We then performed targeted RNAi and CRISPR-Cas9 loss-of-function screens and identified the nuclear export genes (<i>XPO1</i> and <i>KPNB1</i>) as strong vulnerabilities. We observed that these models are sensitive to nuclear export inhibition using the FDA approved therapeutic agent, selinexor (KPT-330). Selinexor treatment of FHWT suppressed <i>TRIP1</i>3 expression, which was required for survival. We further identified <i>in vitro</i> and <i>in vivo</i> synergy between selinexor and doxorubicin, a chemotherapy used in high risk FHWT. Taken together, we identified XPO1 inhibition with selinexor as a potential therapeutic option to treat FHWTs and in combination with doxorubicin, leads to durable remissions <i>in vivo</i>.
Epidemiology: Reports on Research and Teaching 1962.
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
XIV. Medical journalism, 1847-1883
Authors: L. S. King
Journal: JAMA (1983)

In 1883, when<i>JAMA</i>was founded, the United States already had a long tradition of medical journalism, amply covered in recent literature.<sup>1</sup>The first medical journal,<i>The New York Repository</i>, had appeared in 1797 as a quarterly. It survived until 1824, and in its modest life it issued a total of 23 volumes. While several other short-lived journals were published in the early years of the 19th century, two especially important periodicals still continue—the<i>New England Journal of Medicine and Surgery</i>and the<i>American Journal of the Medical Sciences</i>. The former started in 1812 as a quarterly. In 1828 it was consolidated with another journal, the<i>Boston Medical Intelligencer</i>, to become a weekly, the<i>Boston Medical and Surgical Journal</i>. Only in 1928 did the journal, without loss of continuity, assume its present title, the<i>New England Journal of Medicine</i>. What is now the<i>American Journal of the Medical Sciences</i>
Joint Effusions in Sickle Cell-β-Thalassemia Disease
Authors: Ellis J. Van Slyck
Journal: JAMA (1976)

<h3>To the Editor.—</h3> The report of Crout and colleagues (235:1878, 1976) describes joint effusions in a patient in whom they claim a diagnosis of sickle cell-β-thalassemia. The purpose of my letter is not to question the coexistence of this clinical manifestation with the disease ascribed to it, since I have made this observation in my own practice; but I do question their interpretation of the data on which they relied for a diagnosis of sickle cell-β-thalassemia. The hemoglobin values were as follows: hemoglobin S, 86.2%; hemoglobin A2,<sub>2</sub>.5%; and hemoglobin F, 11.3% (the last heterogenously distributed); this pattern can be seen in homozygous sickle cell disease, and is the more likely diagnosis in their case. Although the combination of the β-thal<sup>0</sup>and the sickle gene can produce no demonstrable hemoglobin A<sub>1</sub>, the hemoglobin A<sub>2</sub>value should exceed 3.5%. It is remotely possible that their patient had
DNA diagnosis of neurofibromatosis 2. Altered coding sequence of the merlin tumor suppressor in an extended pedigree
Authors: M. MacCollin
Journal: JAMA (1993)

<h3>Objective.</h3> —To define the DNA mutation causing neurofibromatosis 2 (NF2), a severe genetic disorder involving the development of multiple nervous system tumors in adulthood, in a large, well-studied NF2 pedigree previously used to chromosomally map and to isolate the disease gene. <h3>Design.</h3> —Single-strand conformational polymorphism (SSCP) and DNA sequence analysis of the NF2 gene amplified from affected and unaffected family members. <h3>Participants.</h3> —Affected, unaffected, and at-risk members of a large pedigree segregating NF2, an autosomal dominant disorder caused by inactivation of the<i>merlin</i>tumor suppressor encoded in chromosome band 22q12. <h3>Results.</h3> —A DNA alteration in the<i>merlin</i>coding sequence caused a shift on SSCP gels that was characteristic of the disease chromosome in this NF2 pedigree, being transmitted with the disorder, present only in affected members of the pedigree, absent in unaffected members of the family, and absent from 158 unrelated individuals. The alteration caused substitution of a tyrosine for an asparagine at position 220 of the<i>merlin</i>protein, in a region highly conserved in closely related members of the family of cytoskeletal-associated proteins. The DNA change could also be detected by restriction enzyme digestion with<i>Rsa</i>I. <h3>Conclusion.</h3> —Current practice dictates screening of all those "at risk" for NF2 with magnetic resonance imaging, but the frequency and duration of screening are problematic because of the variable course of the disease. The identification of a DNA alteration in the NF2 gene will permit predictive molecular testing of individuals at risk in this specific family, sparing the expense and emotional burden of protracted screening programs. This information, by providing diagnostic certainty, should also reduce psychological and financial burdens and improve medical care for affected family members. A similar approach to defining the underlying lesion and developing a predictive test is applicable in any documented NF2 family. (<i>JAMA</i>. 1993;270:2316-2320)
THE EFFECTS OF THROMBOSIS AND EMBOLISM OF THE CORONARY ARTERIES.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Economic analysis of targeting chemotherapy (CT) using a 21 gene RT-PCR assay in lymph node negative (LN-), estrogen receptor positive (ER+) early-stage breast cancer (ESBC)
Authors: L. E. Cosler, J. Hornberger, G. H. Lyman
Journal: Journal of Clinical Oncology (2004)

6036 Background: Guidelines for LN-, ER+ adjuvant therapy stratify women into risk categories to optimize decisions concerning adjuvant CT use. A 21 gene RT-PCR assay, Oncotype DX™ Recurrence Score (RS), has been prospectively validated as a predictor of distant recurrence-free survival (DRFS) in the NSABP B-14 study of 668 evaluable LN-, ER+ patients receiving tamoxifen (Paik et al, SABCS 2003). The economic impact of using the RS to guide CT decision-making has not been assessed. Methods: The primary analysis was between (1) No RS Testing and CT if high risk based on NCCN criteria versus (2) RS Testing and CT based on Recurrence Score estimates of 10 yr DRFS. Using estimates of CT efficacy from NSABP B-20, and cancer care costs from CMS and literature, we calculated marginal (added) costs ($), efficacy (life-yrs) and cost-effectiveness (C/E; cost per life-yr gained). Results: Using NCCN criteria, 53 pts (8%) of the 668 pts would be classified as low risk with a 10-yr DRFS of 0.93 (95% CI, 0.86, 1.00). 28% of low risk patients by NCCN criteria would be reclassified to moderate or high risk by the RS. For low risk patients currently not receiving CT, recommending CT based on the Recurrence Score is predicted to increase mean 10-yr DRFS by 0.25 yrs. Using the Recurrence Score as a continuous function to identify the high-risk patients by NCCN that would be reclassified as lower risk, various RS cut-off points were evaluated. For example, model comparisons of treatment based on NCCN criteria versus RS criteria (e.g., RS<10) provide estimates of marginal costs: $1716; effectiveness: 0.6 year; and C/E: $3102/life-yr gained. For pts reclassified by RS as low risk, foregoing CT is also predicted to result in improved quality-adjusted survival. Conclusions: The Recurrence Score assay is a valid prognostic tool in selecting patients for more effective and C/E treatment strategies. The C/E of the RS assay for targeting the addition of adjuvant CT in LN-, ER+ ESBC is well within accepted ranges for healthcare technologies. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Acumen, LLC Genomic Health, Inc.
A Human In Vivo Model for the Determination of Lead Bioavailability Using Stable Isotope Dilution
Authors: Joseph H. Graziano, Conrad B. Blum, Nancy J. Lolacono, Vesna Slavkovich, W. I. Manton, Susan Pond, Michael R. Moore
Journal: Environmental Health Perspectives (1996)

Beverages.stored in lead-cris ias accumula e..trordary concentraons of lead
Neurology
Authors: H. Houston Merritt
Journal: New England Journal of Medicine (1945)

SOME of the recent significant advances and refinements that concern neurology are discussed in the following sections.ElectroencephalographyThe value of the electroencephalogram in convulsive disorders, head injuries and brain tumors has been well established for some time. In recent years the attention of investigators has turned to a great variety of other conditions, and the literature of the past year contains a large number of reports on the results of the use of the electroencephalogram in cases of alcoholism, delirium, behavior problems in children, psychopathic personality, psychoneurosis, psychosis, migraine and cerebral arteriosclerosis, as well as further studies in cases . . .
Mayo Clinic Proceedings, Rochester, Minn
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
STATE MEDICAL EXAMINATIONS OF 1898.
Authors: William Warren Potter
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The place of antimalarials in rheumatology
Authors: R Rynes, T Barrie, Mr Leaver
Journal: Annals of the Rheumatic Diseases (1981)

The place of antimalarials in rheumatology* A conference held in London in November 1980 under the chairmanship of Dr G. R. V. Hughes brought together ophthalmologists and rheumato- logists to discuss the present role of antimalarials in rheumatic diseases, as well as to review the optimal ophthalmological screening required in patients taking long-term therapy.The meeting was prompted by the resurgence of interest in the use of antimalarials, in particular low- dose hydroxychloroquine in systemic lupus, and discussed guidelines for optimal ophthalmological screening, especially in the context of overburdened National Health Service facilities.The principal speakers were 2 rheumatologists,
Cryolmmunotherapy: A Conference Report
Journal: JNCI Journal of the National Cancer Institute (1981)

Journal Article Cryolmmunotherapy: A Conference Report Get access JNCI: Journal of the National Cancer Institute, Volume 67, Issue 5, November 1981, Pages 1173–1176, https://doi.org/10.1093/jnci/67.5.1173 Published: 01 November 1981
Bone Marrow Myeloid-Derived Suppressor Cells (MDSC) Inhibit Graft Versus Host Disease (GVHD) Via An Arginase-1 Dependant Mechanism That Is Upregulated by IL-13
Authors: Steven L Highfill, Paulo Rodriguez, Qing Zhou, Christine A Goetz, Rachelle Veenstra, Patricia A Taylor, Angela Panoskaltsis-Mortari, Jonathan Serody, David Munn, Jakub Tolar, Augusto C Ochoa, Bruce R. Blazar
Journal: Blood (2010)
Modulators of the protein kinase C system influence biliary excretion of cationic drugs
Authors: H Steen
Journal: Hepatology (1993)

To investigate whether hepatobiliary transport of organic cations is under regulatory control, we studied transport of tri-n-butylmethylammonium in the isolated perfused rat liver and in isolated rat hepatocytes. Transport was investigated in the presence of modulators of the protein kinase C and the cyclic AMP second-messenger system. In the isolated perfused rat liver, it was observed that compounds modulating protein kinase C activity clearly affected the biliary excretion process of the cation tri-n-butylmethylammonium. Phorbol 12-myristate 13-acetate, a compound that directly stimulates protein kinase C, elevated the biliary excretion rate of tri-n-butylmethylammonium in a concentration-dependent manner, reaching a twofold increase at 60 nmol/L of the phorbol ester. The inactive derivative 4α-phorbol 12, 13-didecanoate (60 nmol/L) did not show any effect. Vasopressin (48 nmol/L), a receptor-mediated activator of protein kinase C, stimulated the excretion rate of the cation by about 50%. Staurosporin (1 μmol/L), an inhibitor of protein kinase C, clearly decreased the biliary excretion rate of the cation and also blocked its stimulation by phorbol 12-myristate 13-acetate. Neither phorbol 12-myristate 13-acetate nor vasopressin (at concentrations ranging from 10−9 to 10−6 mol/L) affected the initial uptake velocity of tri-n-butylmethylammonium in isolated hepatocytes and isolated perfused livers, whereas staurosporin (1 μmol/L) showed only a modest inhibition of the uptake of the cation. It is inferred that the effect of protein kinase C modulators on hepatobiliary transport of organic cations occurs at the level of carrier-mediated transport in the canalicular membrane. Because bile flow was only slightly affected by these agents, effects on biliary excretion rate of the cation are unlikely to be caused by changes in bile flow. With regard to the cyclic AMP second-messenger system, neither glucagon (concentration range of 10−9 to 10−6 mol/L), a receptormediated activator of adenylate cyclase, nor forskolin (100 μmol/L), a direct activator of adenylate cyclase and dibutyryl cyclic AMP (100 μmol/L), affected the biliary excretion rate and the hepatic uptake rate of the cation in these preparations. In conclusion, cell-to-bile transport of the organic cation tri-n-butylmethylammonium at the canalicular level is directly or indirectly regulated by protein kinase C. Neither the protein kinase C nor the cyclic AMP second-messenger systems seem to be involved in the hepatic uptake process of the cation. (HEPATOLOGY 1993;18:1208-1215).